Category Reports Biotech

Tickers reports and analysis

Replimune ( $REPL) • Biotech • Oncolytic Immunotherapy

Replimune is not a “nice little pipeline story” going into spring 2026. It is a high-beta, high-volatility, very real binary event name whose valuation, narrative, financing flexibility, and strategic credibility are all tied in a major way to one date: April 10, 2026. That is the FDA target action date for the resubmitted BLA for RP1 plus nivolumab in advanced melanoma after anti-PD-1 failure. The market already treated the October 2025 acceptance of the resubmission as a major event, and for good reason. This was not a routine update. It was the market’s signal that the story had gone from post-CRL damage control back to live regulatory possibility.

Altimmune ( $ALT ) May Be One of the Last Shots on Goal in the Obesity-MASH Convergence 2026

After Breakthrough Therapy Designation, 48-week IMPACT data, a financing reset and a clearer 2026 roadmap, the real question is no longer whether Altimmune can generate attention. The real question is whether pemvidutide still deserves to be viewed as one of the last relatively clean independent shots on goal at the intersection of obesity, MASH and broader metabolic-liver disease.

Nektar Therapeutics ( $NKTR ): a full deep dive March 29 2026

Nektar has gone from being, for years, a biotech many investors considered tired and heavily scarred to one of the most discussed U.S. biotech stories of 2025–2026. The reason is not empty narrative. It is the combination of the clinical relaunch of rezpegaldesleukin, two dermatology indications that reignited attention, a balance sheet materially strengthened after the large February 2026 financing, and a pipeline that, while still far from commercial stage, now looks much more readable than it did just twelve months ago.

Wall Street weekly recap ($SPY) and next-week setup – March 30–April 3

The week that just ended was not simply another ugly week for equities. It was a deeper tightening of market tolerance. By Friday, March 27, the S&P 500 had closed at 6,368.85, the Dow at 45,166.64, the Nasdaq at 20,948.36 and the Russell 2000 at 2,449.70. The S&P 500, Dow and Nasdaq all recorded a fifth straight weekly loss, while the Dow confirmed correction territory from its February high and the Nasdaq and Russell were already there. The message was blunt: this is no longer a market that shrugs off macro stress and instantly rotates back into the same crowded stories.

IOVANCE BIOTHERAPEUTICS (NASDAQ: $IOVA) March 27 2026 DD

Iovance enters the next stretch in a very different place than where the bull case used to live. The stock still has a powerful story behind it: AMTAGVI is already commercial, the TIL platform is no longer theoretical, and the company is trying to push that proof into larger and commercially more meaningful opportunities such as NSCLC. But this is also a company that the market punished hard when execution, European regulatory ambition and financing optics stopped matching the earlier narrative. That history matters because it explains why each new positive data point now has to pass a tougher test with investors.

Genmab A/S ( $GMAB ) — Large-Cap Biotech Growth and Pipeline Expansion

Genmab occupies an unusual position in biotechnology. It is neither a pure commercial pharmaceutical company with fully mature revenue streams nor a fragile development-stage biotech whose future depends on one clinical event and the next financing window. That in-between status is precisely what makes the company interesting. It already has a meaningful economic engine through Darzalex-related royalties, yet it still offers real upside if management can broaden the company’s commercial base and sustain the productivity of its antibody platform.

SeaStar Medical ( $ICU )the clinical case is stronger, but the balance sheet still has not caught up . Updated mach 30 with Addendum

SeaStar Medical has spent the last month moving out of the zone where it could be dismissed as a tiny, story-heavy healthcare name with a nice scientific pitch and not much underneath it. The pediatric commercial story is now more tangible, the post-approval burden around SAVE has eased, and the adult pivotal trial has crossed the halfway mark. But that progress has not erased the core financial problem. This is a company with a more credible operating narrative than it had a few months ago, yet still one that openly says it does not have enough capital to fund the next twelve months of planned operations. That tension is the whole ICU story right now.

Corcept Therapeutics ( $CORT ): FDA Approval of Lifyorli and the Path from CRL Devastation to Oncology Redemption

In one of the most striking turnarounds in biotech over the past three months, Corcept Therapeutics has moved from potential extinction to validation of a core thesis. On March 25, 2026, the U.S. FDA approved Lifyorli™ (relacorilant) in combination with nab-paclitaxel for adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic regimens. This is Corcept's second commercially approved product and, more importantly, the first FDA-approved selective glucocorticoid receptor antagonist (SGRA) in oncology.

This approval comes exactly 12 weeks after the December 31, 2025 Complete Response Letter (CRL) that sent CORT plummeting 50% in a single day and raised serious questions about whether Corcept's relacorilant program was a scientific and commercial mirage. It also arrives 5 weeks after the Federal Circuit affirmed that Corcept's key Korlym patents do not prevent Teva's generic, further pressuring the company's legacy cash engine.

The stock opened up +40% on the approval news, erasing much of the CRL damage. But the narrative is now far more complex: Cushing's syndrome access to relacorilant has been effectively closed off until Corcept runs a new trial (likely 3-5 years away), while ovarian cancer and emerging programs in MASH, ALS, and other indications are now in focus. The balance sheet remains strong (>$500M cash, profitable), but investor sentiment has fractured into those betting on Lifyorli's oncology success and those worried about execution, dilution, and the class action lawsuits now pending against management.

Rezolute ( $RZLT ) after the FDA meeting: the congenital HI story is not dead, but the bar is still high

Rezolute remains a classic high-volatility rare-disease biotech story, but the shape of the binary has changed. After sunRIZE missed its primary endpoint in December 2025, many traders effectively treated congenital hyperinsulinism as broken. The March 2026 FDA update forces a more careful read. The agency did not endorse management’s interpretation, yet it also did not dismiss the program outright. Instead, FDA encouraged the submission of comprehensive reports from sunRIZE and the ongoing open-label extension, together with the relevant analysis datasets, for independent evaluation.

ADMA Biologics, Culper Research, and the revenue quality debate ( $ADMA ) (UPDATED march 27 2026 ADMA Fires Back at Culper)

On March 24, 2026, Culper Research disclosed a short position in ADMA Biologics and published a report arguing that the company’s growth story would be overstated by what it described as a channel stuffing scheme involving rebates, extended payment terms, inventory loading, and an undisclosed related-party distributor. Public summaries of the report say Culper’s central claim is stark: absent the alleged sell-in distortion, ADMA’s 2025 revenue would have declined rather than grown. That was enough to break the prior narrative around ADMA as a premium commercial plasma story with unusually strong operating leverage.

Ocugen Inc ( $OCGN ) after the OCU410 12-month readout: alive, arguable, and still risky

There is a lazy way to write this story and a careful way to write it. The lazy way is to say OCU410 either crushed expectations or disappointed the market. The careful way is to admit that the March 24 readout leaves enough evidence for both sides to keep arguing. Ocugen reported that the medium dose chosen for Phase 3 showed a 31% reduction in geographic atrophy lesion growth versus control at 12 months with statistical significance, a 27% slower decline in ellipsoid zone integrity, and no OCU410-related serious adverse events or adverse events of special interest reported to date. That is enough to keep the program alive, credible, and worthy of ongoing attention. It is not enough to eliminate all doubt.

IDEAYA Biosciences ($IDYA): darovasertib timing shift, OptimUM-02 setup, and a full pre-readout deep dive

IDEAYA is one of the more interesting oncology small/mid-cap stories going into spring 2026 because the company sits at the intersection of three things the market tends to pay up for: a registrational catalyst, a platform narrative that is broader than a single-asset biotech, and a balance sheet that is unusually strong for a company still in the clinical stage. The key near-term question is not whether IDEAYA has science or ambition. It does. The real question is narrower and more practical: can darovasertib plus crizotinib in first-line HLA-A2-negative metastatic uveal melanoma deliver a result in OptimUM-02 that is clean enough, strong enough, and regulatorily usable enough to support a credible accelerated-approval path in the United States?

Omeros Corporation ( $OMER ) YARTEMLEA launch, balance-sheet reset, and the real execution test 

Omeros is no longer primarily a regulatory story. That phase changed materially on December 23, 2025, when the FDA approved YARTEMLEA for hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and pediatric patients aged two and older. From that point forward, the central question stopped being “can they get this approved?” and became “can they turn a highly specialized approval into durable commercial traction inside a very concentrated transplant market?”

Weekly recap and next-week setup March 23–27

The week that just ended was not simply another down week for U.S. equities. It was a week in which the market became more severe, more selective and much less willing to pay for fragile narratives. The S&P 500 closed Friday at 6,506.48, the Dow at 45,577.47, the Nasdaq at 21,647.61 and the Russell 2000 at 2,438.45, extending the losing streak for the major U.S. indexes to a fourth consecutive week. The Russell 2000 is now in correction territory from its January high, which matters because it says the weakness is not just about a few mega-cap wobbles. The market is repricing risk appetite more broadly, especially for smaller and more rate-sensitive equities

Travere Therapeutics ( $TVTX ) pre-catalyst deep dive PDUFA APR 13 2026

TVTX is not the typical pre-PDUFA biotech where everything depends on one unproven idea and the balance sheet is already screaming for a financing. Travere enters the April 13, 2026 decision with a drug already commercial in the United States, a meaningful revenue base, a still-usable cash position, and a management team that has already taken FILSPARI from accelerated approval to full approval in IgA nephropathy. That matters. It changes the quality of the setup. It means the market is not being asked to price pure hope. It is being asked to decide how much additional franchise value belongs to FILSPARI if the FDA agrees that the FSGS package is strong enough for approval.

Milestone Pharmaceuticals ( $MIST ) after CARDAMYST approval: from binary FDA story to commercial execution test

Milestone Pharmaceuticals is no longer the same equity story it was in the second half of 2025. For months, the stock traded primarily as a regulatory event setup tied to the resubmitted U.S. application for etripamil in paroxysmal supraventricular tachycardia, or PSVT. That phase ended on December 12, 2025, when the FDA approved CARDAMYST, the company’s first commercial product, as a self-administered nasal spray for the conversion of acute symptomatic episodes of PSVT to sinus rhythm in adults. Since that moment, the question has changed completely. The market is no longer asking whether Milestone can get approved. It is asking whether Milestone can launch, obtain access, build prescription momentum, sustain funding discipline, and then extend the same franchise into atrial fibrillation with rapid ventricular rate, or AFib-RVR.